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Objectives: The number of elderly lung cancer patients requiring surgery has been increasing due to 
the aging society and less invasive perioperative procedures. Elderly people usually have various 
comorbidities, but there are few simple and objective tools that can be used to determine prognostic 
factors for elderly patients with clinical stage I non-small cell lung cancer (NSCLC). The aim of this 
retrospective study was to evaluate the prognostic factors of surgically treated, over 80-year-old 
patients with clinical stage I NSCLC.  
Methods: The preoperative data of 97 over 80-year-old patients with clinical stage I NSCLC were 
collected at Nagasaki University hospital from 1990 to 2012. As prognostic factors, 
inflammation-based scoring systems, including the Glasgow prognostic score (GPS) determined by 
serum levels of C-reactive protein and albumin, the neutrophil lymphocyte ratio (NLR), and the 
platelet lymphocyte ratio (PLR), were evaluated, as well as other clinicopathological factors, including 
performance status, body mass index, carcinoembryonic antigen, Charlson comorbidity index, and 
type of surgical procedure.  
Results: The median age was 82 (range, 80-93) years. There were 62 (64.0%) clinical stage IA cases 
and 35 IB cases. Operations included 64 (66.0%) lobectomies, 15 segmentectomies, and 18 wedge 
resections. The pathological stage was I in 76 (78.4 %) patients, II in 12 (12.4%), III in 8 (8.2%), and 
IV in 1 (1.0%). Twelve (12.4%) patients underwent mediastinal lymph node dissection. Overall 
survival and disease-specific 5-year survival were 55.5% and 70.0%, respectively. The average GPS 
score was 0.4 (0-2). Disease-specific 5-year survival was significantly longer with GPS 0 than with 
GPS 1-2. (74.2%, 53.7%, respectively, p=0.03). Overall 5-year survival was significantly longer with 
GPS 0 that with GPS 1-2. (59.7%, 43.1%, respectively, p=0.005). Both the NLR (median value = 1.9) 
and the PLR (median value = 117) were not correlated with disease-specific and overall 5-year 
survivals. On multivariate analysis, pathological stage I (p=0.01) and GPS 0 (p= 0.04, hazard ratio: 
2.13, 95% confidence interval 1.036-4.393) were significant prognostic factors.   
Conclusions: The preoperative GPS appears to be a useful predictor of overall survival and could be a 














The average age of the population is increasing in most countries including Japan, which has 
already become one of the world’s fastest aging countries. According to the 2013 statistical analysis of 
the Japanese Health and Welfare Ministry, life expectancy was 8.6 years for men and 11.5 years for 
women in their 80s [1]. In addition, non-small cell lung cancer (NSCLC) remains one of the 
commonest causes of cancer deaths worldwide. Recently, several reports have shown that surgery for 
lung cancer in elderly people, including octogenarians, is a safe and feasible treatment [2-6] even for 
nonagenarians [7]. However, surgeons are sometimes reluctant to perform pulmonary resections 
because the surgical mortality and morbidities in elderly people are expected to be higher than in 
younger patients, and the life expectancy of elderly people with lung cancer could be limited by death 
from natural causes [2]. Radiotherapy also yields similar results for early-stage lung cancer [8]. 
Therefore, careful attention has to be paid when deciding the surgical treatment strategy for elderly 
persons. To solve this problem, there have been several reports about prognostic factors for overall 
survival and for postoperative complications [3-5, 9]. Endo et al [5] reported that elderly lung cancer 
patients with a Charlson comorbidity index [9] (CCI) ≥2 had poorer survival. Recently, 
inflammation-based scores have been reported as simple, useful, and objective prognostic predictors 
for cancer patients [10-13]. For example, Leung et al [14] reported that the pretreatment Glasgow 
prognostic score (GPS) was an important predictor of cancer-specific survival in patients with 
inoperable NSCLC. However, these reports were intended for advanced stage patients needing 
chemotherapy [15], not for early-stage patients, such as resectable lung cancer patients. The purpose of 
this retrospective study was to identify the prognostic factors for overall survival of elderly patients 
(80 years and over) with clinical stage I NSCLC 
 








Between 1990 and 2012, 97 patients aged 80 years and over with clinical stage I NSCLC underwent 
pulmonary resection at Nagasaki University Hospital. Patients’ age, sex, performance status (Eastern 
cooperative oncology group: PS), body mass index (BMI), serum carcinoembryonic antigen (CEA), 
CCI, clinical and pathological status, and the type of pulmonary resection and lymph node dissection 
were examined. Three inflammation-based scores, the GPS, the neutrophil lymphocyte ratio (NLR), 
and the platelet lymphocyte ratio (PLR), were also evaluated. Preoperative staging routinely included 
chest X-rays, chest computed tomography (CT), magnetic resonance imaging (MRI) of the brain, and 
positron emission tomography (PET)/CT scan. Clinical N0 was radiographically confirmed by lymph 
nodes with a short axis of less than 1 cm on chest CT and no accumulation of fluorodeoxyglucose on 
PET/CT. Bone scintigraphy and abdominal CT were used until PET/CT could be routinely used. A 
complete evaluation of cardiac and respiratory functions was performed to ensure that patients could 
tolerate pulmonary resection. The extent of pulmonary resection and systemic mediastinal or hilar 
lymph node dissection was determined according to clinical stage, PS, and comorbidity. 
 
Measurement of inflammation-based scores 
 
Glasgow Prognostic Score (GPS), Neutrophil Lymphocyte Ratio (NLR), and Platelet Lymphocyte 
Ratio (PLR) 
 
The GPS was determined as previously described [10]. The GPS consists of two parameters, 
C-reactive protein (CRP) and albumin. Patients with both elevated CRP (>1.0 mg/dL) and 
hypoalbuminemia (<3.5 mg/dL) were allocated a score of 2. Patients with only one of these 
biochemical abnormalities were allocated a score of 1. Patients with neither of these abnormalities 
were allocated a score of 0. The NLR and PLR were calculated as the ratios of the neutrophils and 
platelets to lymphocytes; their median values were used because their distributions were not normal. 
The patients were separated into two groups according to the median values of NLR and PLR, and 






preoperative data. In this study, no patients showed obvious infection or other inflammatory states, 




The relationships among GPS groups were examined using the Kruskal-Wallis test. Disease-specific 
and overall survivals were analysed using the Kaplan-Meier method and the log-rank test. Multivariate 
survival analysis was performed with a Cox proportional hazard regression model. P values less than 





Characteristics of patients and their surgical results 
 
All 97 patients (62 men, 35 women; median age 82 years) underwent pulmonary resection for 
clinical stage I (IA: 62 and B: 35 patients) NSCLC. The preoperative comorbidities of the patients 
included chronic pulmonary disease (35 case, 36.1%), coronary artery disease (19 cases, 19.9%), any 
prior tumour within 5 years (13 cases, 13.4%), diabetes mellitus (10 cases, 10.3%), and so on. These 
comorbidities are shown in Table 1. The surgical procedures included 64 (66.0%) cases of lobectomy, 
15 (15.5%) cases of segmentectomy, and 18 (18.6%) cases of wedge resection. Twelve (12.4%) 
patients underwent mediastinal lymph node dissection. The pathological stage was I in 76 (78.4 %) 
patients, II in 12 (12.4%), III in 8 (8.2%), and IV in 1 (1.0%). No patients died within 30 days of 
surgery. The postoperative comorbidities consisted of atrial fibrillation (9 cases, 9.8%), prolonged (≥7 
days) air leakage (8 cases, 8.2%), pneumonia (7 cases, 7.2%), and so on, all of which were 
successfully treated. Disease-specific and overall 5-year survivals were 70.0% and 55.0%, respectively 






due to other causes, including 3 of pneumonia, 2 of heart failure and fatal arrhythmia, 1 each of 
interstitial pneumonia, cerebral infarction, rectal cancer, panperitonitis, and an accident, while 3 died 
of unknown causes.  
 
Analysis of prognostic factors 
 
  Table 2 shows the characteristics and 5-year survival rates according to potential prognostic factors 
in the clinical stage I elderly people of this study. Four major prognostic factors, including patient 
factors (sex, PS, BMI, serum CEA, and CCI), inflammation factors (GPS, NLR, and PLR), surgical 




PS, BMI, and serum CEA value were not significant, but sex was marginally significant (p=0.05). 
For CCI, the average score was 1.3 (range: 0-5). Disease-specific 5-year survival was not significantly 
different between CCI 0,1 and CCI ≥2 (71.6%, 64.4%, respectively, p=0.48) (Fig.2A), but overall 
5-year survival was significantly longer for CCI 0,1 than for CCI ≥2 (63.2%, 36.5%, respectively, 
p=0.03) (Fig 2B).  
 
Inflammatory factors 
The average GPS score was 0.4 (range: 0-2). Disease-specific 5-year survival was significantly 
longer with GPS 0 that with GPS 1-2 (74.1%, 53.7%, respectively, p=0.03) (Fig.3A). Overall 5-year 
survival was significantly longer with GPS 0 than with GPS 1-2 (59.7%, 43.1%, respectively, 
p=0.005) (Fig.3B). Table 3 shows the patients’ characteristics according to GPS. The patients’ 
background characteristics, including patient, inflammatory, surgical, and stage factors, except for the 
distribution of PLR, were not significantly different among GPS 0, 1, and 2. The median NLR value 






between NLR ≥2 and NLR <2 (p= 0.15, p=0.57, respectively). The median PLR value was 117 (range: 
48-369). Disease-specific and overall 5-year survivals were not significantly different between PLR 
≥118 and PLR<118 (p= 0.66, p=0.34, respectively).  
 
Surgical and Stage Factors 
Surgical procedures (lobectomy / limited, i.e. segmentectomy and wedge resection) and lymph node 
dissection (mediastinal / limited) were not identified as significant prognostic factors (p=0.11, p=0.92, 
respectively). Clinical stage (IA / IB, i.e. tumour size) was also not identified as a significant 
prognostic factor. However, 5-year survival was significantly different between pathological stage I 
and stages II, III, and IV (64.7%, 27.3%, p<0.01)  
Multivariate analysis of overall survival in elderly people with clinical stage I showed that 
pathological stage I (p=0.01, hazard ratio: 2.48, 95% confidence interval) and GPS 0 (p= 0.04, hazard 
ratio: 2.13, 95% confidence interval 1.036-4.393) were significant prognostic factors for a good 




  This retrospective analysis based on individual data of 97 elderly patients who underwent 
pulmonary resection for clinical stage I NSCLC demonstrated that preoperative GPS was a significant 
prognostic factor, as well as pathological stage, which is well known as the most important prognostic 
factor.  
Many countries have been rapidly progressing to become aging societies, and NSCLC still remains 
one of the commonest causes of cancer deaths worldwide. Thus, the number of elderly patients with 
potentially resectable lung cancer will be increasing. On the other hand, aging results in physiological 
deterioration in the respiratory, cardiovascular, and renal systems, and other major organs. In the 
present study, 36% of elderly patients had chronic pulmonary disease, and 20% had coronary artery 






younger patients [16]. Surgeons will have to face the difficult problem of whether to perform surgery 
for such elderly patients with several comorbidities.  
Recently, inflammation-based scores, including the GPS, the NLR, and the PLR, have been 
reported as objective predictors for various cancer patients [10-12], including lung cancer patients [14, 
15, 17]. However, these reports were targeted to advanced stage patients, requiring chemotherapy, 
including patients of various backgrounds. Thus, the present study exclusively investigated the 
usefulness of these inflammation-based scores for surgically resectable elderly patients with clinical 
stage I NSCLC. It is increasingly recognized that the host systemic inflammatory response plays a 
critical role in the development and progression of many cancers [10-15, 17, 18]. The detailed 
mechanism and significance of inflammatory response have been fully described elsewhere [10-15, 17, 
18]. In brief, cancer growth and eventual invasion produce local tissue damage, which disrupts 
homeostasis and incites systemic acute-phase responses [13]. Simultaneously, the progression of 
cancer releases proinflammatory cytokine (i.e. Interleukin 6) and promotes the immunovascular 
system (neutrophils and lymphocytes), and CRP, albumin, neutrophil, platelet and lymphocyte are 
affected and have been used as good ongoing systemic inflammatory response markers in clinical 
practice.  
  McMillan [12] et al reviewed the GPS and reported that it was the most extensively validated of the 
systemic inflammation-based prognostic scores in a variety of clinical scenarios, such as operable 
disease, chemo/radiotherapy, inoperable disease, and even in unselected cohorts. In addition, an 
increased GPS was associated with increased weight and muscle loss, poor PS, increased comorbidity, 
increased pro-inflammatory and angiogenic cytokines, and complications with treatment. In the 
present study, there were no significant differences in background characteristics, BMI, PS and clinical 
and pathological stage among GPS 0, 1, and 2 (Table 3). However, the number of GPS 2 was so 
limited (7 cases) that more cases are needed to whether high GPS is correlated with such parameters. 
On the other hand, the present results showed that disease-specific 5-year survival was significantly 
longer with GPS 0 than with GPS 1-2 (74.1%, 53.7%, respectively, p=0.03). Overall 5-year survival 






Moreover, on multivariate analysis, GPS appeared to be a significant prognostic factor for overall 
survival, even in elderly patients with clinical stage I NSCLC, which seems to have less of an 
inflammatory component than the advanced stage. In fact, though the cases were limited, the 5-year 
survival of GPS 0 (18 cases) and GPS 1-2 (5 cases) in advanced stage (stage II, III and IV) of elderly 
patients were not significant during the same period of this research.    
NLR and PLR have also been reported as prognostic factors [11, 17, 18], and Templeton [18] and 
Zhou [11] et al reviewed the prognostic value of NLR and PLR in various cancers and reported that 
elevated NLR and PLR levels were negative predictors for overall survival in patients with NSCLC 
(hazard ratio=1.66 and 1.85, respectively). Two reasons may explain why NLR and PLR were not 
identified as prognostic factors in the present study.  
First, median values were used as cut-off values for NLR and PLR. However, the NLR and GPS 
have remained controversial because their cut-off values could not be defined consistently. For the 
NLR, according to a meta-analysis of 100 studies [18], the cut-off for high NLR was 4.0 (range = 
1.9-7.2). In the present study, NLR>4 could not be used because only 5 (5.2%) of 97 patients had 
NLR>4. This was not appropriate for statistical analysis. For the PLR, according to a meta-analysis of 
26 studies [11], the cut-off values ranged from 100 to 300 in 26 studies (9 of 26 studies cut-off <160, 
10 studies cut-off ≥160, and the remaining 7 had triple subsets of PLR cut-offs, with six using 150/300 
and one using 100/200). The definition of cut-off values might affect the present results, while the 
GPS was different in that it was categorized using only 3 points (0, 1, and 2). We would recommend 
using the GPS more than the NLR and PLR as inflammation-based scores for clinical stage I NSCLC. 
Second, this retrospective study involved elderly patients with clinical stage I NSCLC, which is 
regarded as an early stage of cancer. Thus, a significant effect of systemic inflammation might not be 
identified by NLR and PLR. 
  Other factors including patients’ factors (PS, BMI, and serum CEA), surgical factors (procedures 
and lymph node dissection), and clinical stage were not identified as significant prognostic factors, 
except for sex (marginally significant p=0.05). We should accept these results, especially surgical 






overall survival and local recurrence rates between the with and without lymph node dissection groups 
for elderly patients with clinical stage I NSCLC and concluded that a limited operation without lymph 
node dissection might be the best surgical treatment for carefully selected elderly patients with clinical 
stage I NSCLC.  
In addition, the small sample size of the present study might affect other typical prognostic factors, 
PS and CEA [20]. From the results of the present study, we suggest the following for determining the 
appropriateness of surgery for elderly patients with clinical stage I NSCLC. Surgical candidates 
basically require a good performance status and preserved respiratory and cardiac functions for 
procedures, and a low score GPS is desirable. Radical pulmonary resection is not always necessary, 
and VATS is the best approach [21] because it is less invasive [22] and less painful [23]. On the other 
hand, a patient with GPS ≥2 might benefit less from surgery. Thus, high GPS would change our 
clinical practice in regards to management of elderly lung cancer patients. 
This study had several limitations. First, this study was retrospective, and the sample population 
was small and median follow-up of only 2.8 years and obtained from a single institution; small 
samples and short time of follow-up sometimes affect statistical accuracy. Secondly, since cut-off 
values of NLR and PLR have not been defined, they might not have been identified as prognostic 
factors. Thirdly, the long period of time examined (23years) during which many diagnostic and 
technical advances, such as PET/ CT, VATS and postoperative intensive care evolved. This long period 
of time would be another selection bias. Thus, we should have limited the analysis to a short time 
during which all the patient management had been homogenous. Future studies are needed to address 
these limitations and to determine whether this inflammation-base score could be applied in clinical 
practice to help determine the appropriateness of surgery for elderly or younger patients, or advanced 
stage with NSCLC.   
In conclusion, to the best of our knowledge, this is the first study to evaluate the prognosis of 
elderly patients with operable clinical stage I NSCLC using the preoperative GPS. The preoperative 
GPS should be used routinely in clinical practice, since it appears to be a useful predictor of overall 




















Table 1. Preoperative comorbidities of elderly patients 
Comorbidity Number of patients % 
Chronic pulmonary disease 35 36.1 
Coronary artery disease 19 19.9 
Any prior tumour within 5 years 13 13.4 
Diabetes mellitus 10 10.3 
Cerebrovascular disease 6 6.2 
Peripheral vascular disease 5 5.2 
Moderate to severe renal disease 5 5.2 
Congestive heart failure 3 3.1 
Connective tissue disease 3 3.1 
Peptic ulcer disease  2 2.1 







Table 2.  5-year survival rates according to potential prognostic factors in clinical stage I elderly 
patients with NSCLC 
Factors Variable 
Number                   
of patients 
5-year                                    
survival (%) 
p value 
Patient            
Factors  
Sex                                                          
(male / female) 
62 / 35 43.3 / 71.7 0.05 
 
Performance Status                                        
(0 / 1, 2) 
58 / 39 70.5 / 47.7 0.06 
 
Body Mass Index                                             
( < 22 / ≥22 kg/m2) 
46 / 51 53.5 / 56.5 0.84 
 
CEA                                                             
(≤5 / >5 ) 
65 / 32 49.8 / 62.2 0.89 
 
CCI                 
(0,1 / ≥2) 
64 / 33   
    Overall  63.2 / 36.5 < 0.05 
    Disease-Specific  71.6 / 64.4 0.48 
     
Inflammatory                         
Factors 
GPS             
(0 / 1, 2) 
   
    Disease-Specific  65 / 32 74.1 / 53.7 < 0.05 
    Overall   59.7 / 43.1 < 0.01 
 
NLR                    
(< 2 / ≥2) 
   
    Disease-Specific  54 / 43 64.9 / 80.1 0.15 
    Overall   49.7 / 68.2 0.57 






(< 118 / ≥118) 
    Disease-Specific  49 / 48 73.4 / 66.8 0.66 
    Overall   51.8 / 60.7 0.34 
     
Surgical               
Factors 
Surgical procedure         
(Lobectomy / Limited) 
64 / 33 59.6 / 41.2 0.11 
 
Lymph node dissection         
(ND2 / Limited) 
21 / 76 54.9 / 56.5 0.92 
     
Stage                
Factors 
Clinical Stage                
(IA / IB) 
62 / 35 50.4 / 58.2 0.67 
  
Pathological Stage             
(I / II, III, IV) 
76 / 21 64.7 / 27.3  < 0.01 
 
CEA: Carcinoembryonic antigen 
CCI: Charlson Comorbidity Index  
GPS: Glasgow Prognostic Scale 
NLR: Neutrophil Lymphocyte Ratio 
PLR: Platelet Lymphocyte Ratio 











Table 3. Patient characteristics according to the Glasgow Prognostic Score  
      
    GPS 0 GPS 1 GPS 2 p value 
Number (%) Patients 65 (67.0) 25 (25.8) 7 (7.2)  
      
Patient              
Factor  
Age (median)  82 82 83 0.41 
 Sex     
    Male 40 (61.5) 15 (60.0) 7 (100) 0.12 
    Female 25 (38.5) 10 (40.0) 0 (0)  
 Performance Status     
    0 42 (64.6) 11 (44.0) 5 (71.4) 0.24 
    1 20 (30.1) 14 (56.0) 2 (28.6)  
    2 3 (4.6) 0 (0) 0 (0)  
 Body Mass Index      
    ≤22 kg/m2 31 (47.7) 10 (40.0) 5 (71.4) 0.57 
    >22 kg/m2 34 (52.3) 15 (60.0) 2 (28.6)  
 Respiratory function     
    FEV1.0 (ml: average) 1904 1761 1859 0.52 
    %DLCO (%: average) 92 81 100 0.10 
 CEA      
    <5  21 (32.3) 9 (36.0) 2 (28.6) 0.37 
    ≥5 44 (67.7) 16 (64.0) 5 (71.4)  
 CCI     
    0 19 (29.2) 7 (28.0) 0 (0) 0.17 






    ≥2 21 (32.3) 8 (32.0) 4 (57.1)  
      
Inflammatory         
Factor 
NLR     
    <2 34 (52.3) 17 (68.0) 3 (42.9) 0.17 
    ≥2  31 (47.7) 8 (32.0) 4 (57.1)  
 PLR     
    < 118 27 (41.5) 18 (72.0) 4 (57.1) 0.04 
    ≥118 38 (58.5) 7 (28.0) 3 (42.9)  
      
Surgical             
Factor 
Surgical procedure      
    Lobectomy 47 (72.3) 15 (60.0) 2 (28.6) 0.05 
    Limited 18 (27.7) 10 (40.0) 5 (71.4)  
 Lymph node     dissection      
    ND2 15 (23.1) 5 (20.0) 1 (14.3) 0.84 
   Limited 50 (76.9) 20 (80.0) 6 (85.7)  
      
Stage                 
Factor 
Clinical Stage      
    IA 46 (70.8) 12 (48.0) 4 (57.1) 0.12 
    IB 19 (29.2) 13 (52.0) 3 (42.9)  
 Pathological Stage      
    I 54 (83.1) 17 (68.0) 5 (71.4) 0.23 
    II 7 (10.8) 4 (16.0) 1 (14.3)  






     IV 0 1 (4.0) 0   
      
GPS: Glasgow Prognostic Scale 
FEV1.0: Forced expiratory volume in one second 
%DLCO: %diffusing capacity for carbon monoxide 
CEA: Carcinoembryonic antigen 
CCI: Charlson Comorbidity Index  
NLR: Neutrophil Lymphocyte Ratio 
PLR: Platelet Lymphocyte Ratio 















Table 4.   Multivariate analysis of survival in clinical stage I elderly people: Cox proportional hazard 
model 
Factors Variable Reference Hazard Ratio 95% CI p value 
Patient           
Factors 
Sex (male) female 1.57 0.661 - 3.716 0.31 
 
Inflammatory       
Factors 
CCI (2-) 0, 1 1.60  0.578 - 4.395 0.34 
 
 
GPS (1, 2) 0 2.13 1.036 - 4.393 0.04 
Stage              
Factors 
p-Stage                 
(II, III, IV) 
I 2.48 1.211 - 5.076 0.01 
 
CCI: Charlson Comorbidity Index  
GPS: Glasgow Prognostic Scale 














Fig. 1. Disease-specific and overall survival curves in elderly clinical stage I lung cancer patients. 
Disease-specific and overall 5-year survivals are 70.0% and 55.5%, respectively.  
 
Fig. 2. Comparisons of disease-specific survival curves (A) and overall survival curves (B) between 
Charlson comorbidity index (CCI) 0,1 (n=64) and CCI ≥2 (n=33). Disease-specific 5-year survival is 
not significantly different between CCI 0,1 and ≥CCI 2 (71.6%, 64.4%, respectively, p=0.48). Overall 
5-year survival is significantly longer with CCI 0,1 than with CCI ≥2(63.2%, 36.5%, respectively, 
p=0.03) 
 
Fig. 3. Comparisons of disease-specific survival curves (A) and overall survival curves (B) between 
Glasgow prognostic score (GPS) 0 (n=65) and GPS 1+2 (n=32). Both 5-year survival rates are 
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